In this study, we evaluated a rapid whole-blood test, BM-test Helicobacter pylori, for detection of H. pylori infection in 144 and 48 patients with other gastrointestinal symptoms and with gastric cancer, respectively. The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of the test correlated well with the standards used for the calculation, i.e., serology by enzyme-linked immunosorbent assay or culture and histology.
inger Mannheim]) were performed with sera and blood samples from all patients.
Test procedure. Patient blood samples were tested for infection with H. pylori according to the manufacturer's instructions. Briefly, blood was drawn with a heparin-treated glass capillary. The capillary was inserted into lysis buffer, and the solution was poured on the indicator test field membrane. When the solution had passed through, the membrane was dried with a cotton swab. Then, solution containing goat antihuman immunoglobulin G (IgG) attached to colloidal gold was added to the membrane. When this solution had drained through the test area, the result was visible; a positive test was indicated by two red spots on the membrane, one test spot with H. pylori antigens and one control spot with human IgG. Only the control spot was positive for a result considered negative.
Test evaluation. When the BM-test Helicobacter pylori was evaluated, either serology or culture and histology were considered the standard for the calculations. The sensitivity and specificity, as well as the PPV, NPV, and diagnostic accuracy, of the BM-test Helicobacter pylori were calculated for both groups independently and together. PPV was calculated as the portion of true-positive patients among all of the patients who were scored positive, and the NPV was calculated as the portion of true-negative patients among all of the patients who were scored negative according to the "gold standard" used. Diagnostic accuracy was calculated as the percentage of the total number of patients tested who were correctly scored, i.e., who were either positive or negative for H. pylori by both the BM-test Helicobacter pylori and the standard used.
Test color intensity scores versus ELISA. The BM-test Helicobacter pylori was also evaluated according to the color intensity of the obtained test spot on the membrane compared to the mean absorbance at 450 nm recorded by ELISA measurements. The color intensity of the test spot was scored visually, by three persons, from negative to positive in five steps and was compared with that of the control spot (Fig. 1) .
Visualization of spots was scored as follows: negative, only the control spot visible; pos(ϩ), slightly visible test spot; posϩ, less color intensity than that of the control spot; posϩϩ, same color intensity as that of the control spot; posϩϩϩ, moreintensive color than that of the control spot.
Results. In the GC group, 21 of 48 patients (43.8%) were verified as H. pylori positive by culture and histology and 32 of 46 patients (69.6%) were verified by serology. In the GI group, 69 of 144 patients (47.9%) were H. pylori positive as determined by culture and histology and 83 of 144 patients (57.6%) were positive by serology. The sensitivity, specificity, PPV, NPV, and diagnostic accuracy results of the BM-test Helicobacter pylori for the GC and GI groups, which were calculated for both groups independently and together, are presented in Table 1 . Sensitivity ranged from 88 to 96%, and specificity ranged from 44 to 95%. PPVs ranged from 0.57 to 0.96, NPVs ranged from 0.77 to 0.96, and the diagnostic accuracy varied from 67 to 91%. The total number of false BM-test Helicobacter pylori results when intensity was scored by the naked eye, as well as the correlation with the ELISA absorbances measured at 450 nm, is presented in Table 2 . False-negative and falsepositive results versus serology were 7 and 4%, respectively, i.e., in total giving a false result for about 11% of the samples tested. Diagnostic accuracy overall for the whole-blood test is, therefore, 89%. Visual color intensity scores of the test spots for BM-test Helicobacter pylori versus mean absorbance at 450 nm obtained by ELISA are plotted in Fig. 1 . The test results with the former test, based on whole-blood samples, were obtained within 15 min, compared to several hours for conventional ELISAs.
Discussion. The rapid BM-test Helicobacter pylori is an easy screening test with high sensitivity and specificity for patients with GI symptoms other than GC. Overall, the BM-test Helicobacter pylori results corresponded well with ELISA, culture, and histology results. From Fig. 1 , the amounts of antibodies in the serum samples seem to correspond well with the amounts of antibody that the antigen in the test spot is able to detect in whole blood from the same patients. Thus, the semiquantitative test for whole-blood samples is almost as reliable as an ELISA but gives results that are only either positive or negative for diagnosing H. pylori infection. However, there was a high number of GC patients with false-negative H. pylori results as determined by culture and histology compared to those by serology, which is in accordance with other studies of cancer patient serology in which the age of the patients seemed to influence the antibody titers (8, 16) . The wide percentage ranges observed in the results for sensitivity, specificity, NPV, PPV, and diagnostic accuracy depended on the standard used for calculations for thee two different patient groups. Cutoff values for serology-based ELISA kits may have to be reduced for determination of H. pylori status among elderly patients, in whom the immune system has a decreased activity (19) . It could also be that colonization with H. pylori is not detected in some patients at endoscopy, due to the patchy distribution of the bacteria in the gastric mucosa which is observed in discrepancies between culture, histology, and serology results (1). When culture and histology are used to diagnose H. pylori infection in patients with GC, there may be a higher percentage of infection than that determined by these two conventional methods. Patients with previous H. pylori infections could consequently still be classified H. pylori positive by se- rology and immunoblotting, although they present negative results by culture and histology (6) (7) (8) 10) . Antibodies toward the CagA protein seem to persist for a prolonged time in patient sera compared to other antibodies raised in the body toward other H. pylori antigens. It could, therefore, be possible to use this specific protein as a marker for previous H. pylori infection (2, 4). In future diagnostic evaluations, detection of anti-CagA antibodies by immunoblotting may be a useful method to give a correct H. pylori status in patients with GC (15) .
In earlier studies with the same diagnostic kit, which was previously called Helisal (Cortecs Ltd.), endoscopy patients referred to GI units due to dyspeptic symptoms were included (12) (13) (14) 20) . A comparative study of Helisal whole-blood, serum, and saliva tests was also performed with patients attending a GI clinic, with a [
13 C]urea breath test as the gold standard (9) . No evaluation studies of a rapid whole-blood test for patients with GC have been performed. Furthermore, no previous study with this diagnostic kit has been performed or reported for a Scandinavian population. At least five other rapid diagnostic kits, FlexSure HP (SmithKline Diagnostics, Inc.) for serum (5), Pyloriset Dry (Orion Diagnostica) for serum (11), Pyloriset screen (Orion Diagnostica) for whole blood, H. PYLORICHEK (EY Laboratories, Inc.) for serum (17) , and the QuickVue One-Step H. pylori test (Quidel) for serum, plasma, and whole-blood specimens, are also commercially available (3, 18) . One kit, H. PYLORICHEK, was evaluated with 239 subjects in California, giving 100% sensitivity and specificity as well as 100% accuracy by conventional serology testing (17) . All studies report that there exist differences in the obtained sensitivities and specificities depending on the setting of the study and age of the patients, as well as the disease status of the study subjects.
To summarize, the BM-test Helicobacter pylori rapid wholeblood test gives a good approximation of H. pylori status for a large number of patients when GC is ruled out. Furthermore, our results from the whole-blood test seem to correspond well with the amount of antibodies present in the sera as determined by ELISA; the higher the amount of antibody in the sample observed by serology, the stronger and more secure is the visual scoring of the rapid test, since the possibility of error in the reading is reduced with a strong test reaction. The whole-blood test could, therefore, be used as an aid in hospitals and by general practitioners for the rapid diagnosis of H. pylori infection. Culture and histology seem not to be necessary to verify diagnosis when ELISA is used, even though these procedures may still be recommended before and/or after eradication therapies are given. 
